WeVote
Log In

Bill

Bill

A 7311

Requires certain health insurance policies and contracts to provide coverage for human leukocyte antigen testing for use in tissue typing for bone marrow testing

2025 Regular Session Introduced by Gary Pretlow

Requires NY health plans to cover HLA tissue-typing tests for bone marrow transplantation, reducing out-of-pocket costs and expanding access for patients needing donor matching.

REFERRED TO INSURANCE
0
WeVote Research Nonpartisan
Bill Summary · A 7311

Summary of Bill A 7311

Overview

Bill A 7311 would require certain New York health insurance policies and contracts to provide coverage for human leukocyte antigen (HLA) testing used in tissue typing for bone marrow testing. The bill is currently in the early stage of the legislative process, having been introduced on March 25, 2025 and referred to the Assembly Insurance Committee.

Purpose and Intent

  • To ensure that HLA testing used for tissue typing in the context of bone marrow transplantation is covered as a benefit under health insurance plans.
  • Aims to reduce potential out-of-pocket costs or access barriers for individuals needing HLA typing to determine donor-recipient compatibility for bone marrow transplants.

Key Provisions (as stated)

  • Requires certain health insurance policies and contracts to provide coverage for HLA testing used in tissue typing for bone marrow testing.
  • The exact scope (which plans are covered, any exemptions, and any cost-sharing limits) is not detailed in the provided information. The bill text would define terms, conditions, and any exceptions in full.

Affected Parties

  • Individuals insured under covered health insurance policies and contracts.
  • Insurers offering the relevant health plans in New York (including types of plans that fall under “certain health insurance policies and contracts” as defined in the bill).
  • Health care providers and laboratories performing HLA tissue-typing tests for bone marrow transplantation.

Legislative Action and Timeline

  • Introduced: March 25, 2025.
  • Status: Referred to Assembly Insurance (listed twice in the provided actions, indicating the same referral).
  • Next potential steps: The Insurance Committee could hold hearings, propose amendments, and advance the bill to subsequent committees or floor action.

Sponsor and Related Legislation

  • Primary sponsor: J. Gary Pretlow.
  • Related bills from prior sessions (suggesting ongoing policy interest in HLA testing coverage): A 1540, A 3031, A 6459, A 4988, A 4084, A 1769, A 3694, A 1793, A 4798.
    • These prior-session bills indicate a broader, continuing effort to secure insurance coverage for HLA testing and related tissue-typing for bone marrow transplantation.

Potential Impact

  • Positive coverage implications for patients requiring bone marrow transplantation, potentially reducing financial barriers to essential diagnostic testing.
  • May influence insured populations by expanding benefits to include a specific, clinically relevant genetic/tissue-typing service.
  • Insurers may need to adjust policy language and claims processing to align with the new coverage requirement once enacted.

Notes

  • The specific operational details (eligibility, plan applicability, cost-sharing, exclusions, administrative processes) will be defined in the bill’s full text. The current information provides the core objective and fiscal/administrative implications are contingent on final language.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.